文献速递慢性肾脏病肾血管病与高血压

血管紧张素II 1型受体结合分子在慢性肾脏病模型高血压中起关键作用

An angiotensin II type 1 receptor binding molecule has a critical role in hypertension in a chronic kidney disease model.
PubMed 文献 · Kidney Int · 2017-01-10

在小鼠残余肾慢性肾脏病模型中,129/Sv小鼠5/6肾切除后肾脏ATRAP表达下降并出现高血压,C57BL/6小鼠ATRAP表达升高且不易进展为高血压;C57BL/6背景的ATRAP敲除小鼠5/6肾切除后出现高血压伴血浆容量增加,肾脏上皮钠通道α亚基和肿瘤坏死因子-α表达及肾细胞膜血管紧张素II 1型受体显著增强。

要点

  • 129/Sv小鼠5/6肾切除后肾脏ATRAP表达下降并出现高血压。
  • C57BL/6小鼠5/6肾切除后肾脏ATRAP表达升高且不易进展为高血压。
  • C57BL/6背景ATRAP敲除小鼠5/6肾切除后出现高血压伴血浆容量增加。

核心结论

  • 肾脏ATRAP下调参与肾质量减少所致血压升高的发生和进展,提示ATRAP是慢性肾脏病高血压的治疗靶点。

研究设计与样本

  • 在小鼠残余肾慢性肾脏病模型中,比较C57BL/6和129/Sv小鼠5/6肾切除后肾脏内源性ATRAP表达,并进一步在高血压抵抗的C57BL/6背景ATRAP敲除小鼠中行5/6肾切除。

主要发现

  • 129/Sv小鼠5/6肾切除后肾脏ATRAP表达下降并出现高血压,C57BL/6小鼠肾脏ATRAP表达升高且抵抗进行性高血压。
  • C57BL/6背景ATRAP敲除小鼠5/6肾切除后出现高血压伴血浆容量增加。
  • 5/6肾切除后,敲除小鼠较野生型C57BL/6小鼠肾脏上皮钠通道α亚基和肿瘤坏死因子-α表达显著增强,同时肾脏细胞膜血管紧张素II 1型受体增加。

临床怎么用

  • 作者认为肾脏ATRAP下调参与肾质量减少所致血压升高的发生和进展,并提示ATRAP是慢性肾脏病高血压的治疗靶点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Angiotensin II type 1 receptor-associated protein (ATRAP) promotes AT1R internalization along with suppression of hyperactivation of tissue AT1R signaling. Here, we provide evidence that renal ATRAP plays a critical role in suppressing hypertension in a mouse remnant kidney model of chronic kidney disease. The effect of 5/6 nephrectomy on endogenous ATRAP expression was examined in the kidney of C57BL/6 and 129/Sv mice. While 129/Sv mice with a remnant kidney showed decreased renal ATRAP expression and developed hypertension, C57BL/6 mice exhibited increased renal ATRAP expression and resistance to progressive hypertension. Consequently, we hypothesized that downregulation of renal ATRAP expression is involved in pathogenesis of hypertension in the remnant kidney model of chronic kidney disease. Interestingly, 5/6 nephrectomy in ATRAP-knockout mice on the hypertension-resistant C57BL/6 background caused hypertension with increased plasma volume. Moreover, in knockout compared to wild-type C57BL/6 mice after 5/6 nephrectomy, renal expression of the epithelial sodium channel α-subunit and tumor necrosis factor-α was significantly enhanced, concomitant with increased plasma membrane angiotensin II type 1 receptor in the kidneys. Thus, renal ATRAP downregulation is involved in the onset and progression of blood pressure elevation caused by renal mass reduction, and implicates ATRAP as a therapeutic target for hypertension in chronic kidney disease.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Kobayashi R, Wakui H, Azushima K, et al. An angiotensin II type 1 receptor binding molecule has a critical role in hypertension in a chronic kidney disease model. Kidney Int. 2017. PMID: 28081856. doi:10.1016/j.kint.2016.10.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。